Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Autism Spectrum Disorder
Interventions: Continuous Theta Burst Stimulation; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 11 Years to 25 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autonomic Nerve Block
Interventions: Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine, Pecto-intercostal Fascial Block with normal saline; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hepatitis b Virus, Hepatitis B
Interventions: HepB mAb19, Sterile Saline; Biological · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Allergic Conjunctivitis
Interventions: olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale, Placebo; Drug
Lead sponsor: Andover Research Eye Institute; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Celiac Disease
Interventions: larazotide acetate, placebo, 900 mg gluten; Drug · Dietary Supplement
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Colorado Springs, Colorado • Chicago, Illinois + 14 more

Conditions: Meniere's Disease
Interventions: OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more

Conditions: Psoriatic Arthritis
Interventions: Apremilast 30 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more

Conditions: Epilepsy
Interventions: Phenobarbital, Placebo; Drug · Other
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Fragile X Syndrome
Interventions: AZD7325 (High-Dose), AZD7325 (Low-Dose), Placebo oral capsule; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Oral Mucositis, Head and Neck Cancer
Interventions: EN3285, Placebo, Standard of care; Drug · Other
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Louisville, Kentucky • Houston, Texas

Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: APF530, dexamethasone, Palonosetron Hydrochloride, placebo; Drug · Other
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 52
States / cities: Anniston, Alabama • Glendale, Arizona • Tucson, Arizona + 46 more

Conditions: Pemphigus Vulgaris
Interventions: Enbrel (Etanercept); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Musculoskeletal Complications, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: naproxen, placebo; Drug · Other
Lead sponsor: Gary Morrow; Other
Eligibility: 18 Years to 120 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 16
States / cities: Honolulu, Hawaii • Decatur, Illinois • Evanston, Illinois + 13 more

Conditions: Neuropathic Pain
Interventions: AZD2423, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 11 more

Conditions: Colitis, Ulcerative
Interventions: BMS-986165, Placebo Comparator; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: San Diego, California • Arlington Heights, Illinois • Shreveport, Louisiana + 7 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Giant Cell Arteritis
Interventions: mavrilimumab, placebo, prednisone; Combination Product · Drug
Lead sponsor: Kiniksa Pharmaceuticals, Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Sarasota, Florida • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Neuropathic Pain
Interventions: SAR292833, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Tucson, Arizona • Garden Grove, California • Newport Beach, California + 24 more

Conditions: Prostate Cancer
Interventions: LY2452473, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 19 Years and older · Male only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Gainesville, Florida • Baltimore, Maryland • Boston, Massachusetts

Conditions: Alcohol Dependence, Problem Drinking, Hazardous Drinking, Human Immunodeficiency Virus, AIDS
Interventions: Vivitrol- Intramuscular naltrexone (depot-formulation), Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Migraine
Interventions: Xeomin, Placebo; Drug
Lead sponsor: Merz Therapeutics GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 48
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Safety
Interventions: Single intravenous doses of RC-01, Single intravenous doses of placebo, Multiple intravenous doses of RC-01, Multiple intravenous doses of placebo; Drug
Lead sponsor: Recida Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Type 2 Diabetes
Interventions: Cocoa polyphenols; Dietary Supplement
Lead sponsor: Arpita Basu; Other
Eligibility: 21 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Search by objective public record fields.

Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Sternotomy PIFB Block in Open Heart Surgery

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

OTO-104 for Meniere's Disease

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Study of Phenobarbital Inhibition of Catamenial Epilepsy

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris

Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

KPL-301 for Subjects With Giant Cell Arteritis

Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Alcohol Pharmacotherapy for HIV+ Prisoners

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes